Bevacizumab as adjuvant therapy for lung cancer does not help patients over 65

BMJ 2012; 344 doi: (Published 19 April 2012) Cite this as: BMJ 2012;344:e2855
  1. Bob Roehr
  1. 1Washington, DC

There is no substantial benefit for patients over 65 in adding bevacizumab (Avastin) to the standard treatment of carboplatin and paclitaxel for non-small cell lung cancer, a study shows (JAMA 2012;307:1593).

Bevacizumab gained that additional indication in 2006 based on a trial where two thirds of the patients were younger than 65, despite the …

View Full Text

Log in

Log in through your institution


* For online subscription